TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34552937
Drug: Conventional Nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Nutritional Therapy including Low-FODMAP Diet
Study: 34553156
Drug: Elagolix 200
Normalized name: elagolix 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elagolix 200 mg administered in early follicular phase
Study: 34553156
Drug: Elagolix 200
Normalized name: elagolix 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elagolix 200 mg administered in midluteal phase
Study: 34553156
Drug: Elagolix 200
Normalized name: elagolix 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elagolix 200 mg administered in late follicular phase
Study: 34555420
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg orally and misoprostol 800 mcg buccally dispensed by mail-order pharmacy after in-person clinical assessment
Study: 34555420
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg orally and misoprostol 800 mcg buccally dispensed by mail-order pharmacy
Study: 34556099
Drug: Proposed solutions
Normalized name: Propoven
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proposed solutions for ethical involvement of adolescents in HIV research
Study: 34556171
Drug: First COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: First COVID-19 surge treatment
Study: 34556171
Drug: Second COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second COVID-19 surge treatment
Study: 34557402
Drug: Rituximab treatment
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab treatment in phase 3 randomized trial NHL-001 (NCT01852435)
Study: 34557558
Drug: mRNA COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA COVID-19 vaccination <40 days after COVID-19-specific monoclonal antibody therapy
Study: 34557558
Drug: COVID-19-specific monoclonal
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19-specific monoclonal antibody therapy
Study: 34557563
Drug: Oral ART
Normalized name: Aquoral Artificial Saliva Protective Oral Spra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ART
Study: 34558040
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg every 3 weeks for ≤ 24 months
Study: 34559026
Drug: Drug-related problem
Normalized name: Psoriasin Problem Skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-related problem days
Study: 34559354
Drug: Oral complementary
Normalized name: 20-mer complementary to Akt mRNA
DrugBank: Archexin (DB05971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral complementary and alternative medicine (OCAM) use
Study: 34559851
Drug: CBE Intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBE Intervention (6 months): aerobic, strength, balance and flexibility training for 90 minutes, 3 times/week, with weekly supervised coaching.
Study: 34560047
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole treatment
Study: 34561293
Drug: SABA prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: SABA prescriptions (≥3 canisters)
Study: 34561293
Drug: SABA prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: SABA prescriptions (3-5, 6-9, 10-12, ≥13 canisters)
Study: 34561812
Drug: Belantamab mafodotin
Normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belantamab mafodotin (2.5 mg/kg)
Study: 34561812
Drug: Selinexor plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor plus dexamethasone (80 mg + 20 mg)
Study: 34562103
Drug: Lp-PLA2 inhibitor
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lp-PLA2 inhibitor
Study: 34562149
Drug: Inulin (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inulin (1.0 g/dL) administered intravenously at a priming rate of 8 mL/kg/hr for 30 min, followed by a maintenance rate of 0.7 × eGFR mL/min/1.73 m².
Study: 34562149
Drug: Inulin (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inulin (1.0 g/dL) administered intravenously.
Study: 34562193
Drug: Self-administered flavor
Normalized name: blackberry flavor
DrugBank: Blackberry (DB10628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered flavor test (four solutions: coffee, peppermint, banana)
Study: 34562193
Drug: Self-administered flavor
Normalized name: blackberry flavor
DrugBank: Blackberry (DB10628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered flavor test
Study: 34562230
Drug: Selinexor 60
Normalized name: selinexor 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor 60 mg QW in combination with carboplatin and paclitaxel (CT)
Study: 34562313
Drug: Raltegravir 400
Normalized name: raltegravir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 400 mg orally twice daily for 6 months
Study: 34562489
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% (3 mL) + Lidocaine 2% (3 mL) + Hyaluronidase 150 IU (1 mL), initial volume 7 mL, adjusted based on previous patient response.
Study: 34563240
Drug: Shorter treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shorter treatment regimens containing new drugs (39-week multi-drug regimens)
Study: 34563945
Drug: Entinostat (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entinostat (4 mg, 6 mg, or 8 mg orally on days 1 and 8) plus Clofarabine (10 mg/m2)
Study: 34564048
Drug: Tumor necrosis
Normalized name: Tumor necrosis factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor necrosis factor receptor 1 (TNF-R1) levels in men with CoA
Study: 34564048
Drug: Tumor necrosis
Normalized name: Tumor necrosis factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor necrosis factor receptor superfamily member 10B (TRAIL-R2) levels in men with CoA
Study: 34564694
Drug: Lenalidomide 25
Normalized name: lenalidomide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 25 mg days 1-10 of each cycle plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) for six cycles
Study: 34564694
Drug: Lenalidomide 25
Normalized name: lenalidomide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 25 mg days 1-10 of each cycle plus R-CHOP
Study: 34564955
Drug: High mutations
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High mutations in fatty acid metabolism pathway (mut-high)
Study: 34565452
Drug: One-carbon metabolism
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-carbon metabolism analysis in 1-year-old children
Study: 34568066
Drug: Treosulfan-based conditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treosulfan-based conditioning regimen (42 g/m²)
Study: 34569847
Drug: Evidence-based pediatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based pediatric weight management intervention (PWMI); details on dosage and duration not available.
Study: 34570534
Drug: Mindfulness training
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindfulness training (not specified dosage or duration)
Study: 34570655
Drug: DA-EPOCH-R regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-EPOCH-R regimen (dose-adjusted etoposide, doxorubicin, cyclophosphamide with vincristine and prednisone plus rituximab)
Study: 34572852
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy followed by potentially curative gastric cancer resection
Study: 34572852
Drug: Other events
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other events (concurrent distant metastasis, locoregional recurrence or death)
Study: 34579646
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma transfusion (CP); median infusion titers 1:320 U/mL (Interquartile range 1:80-1:320)
Study: 34579767
Drug: WJ-MSC and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: WJ-MSC and rEMS combination (Group 1)
Study: 34579775
Drug: Sacubitril/valsartan (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan (target dose 97/103 mg b.i.d.)
Study: 34579786
Drug: Immediate bivalent
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate bivalent HPV vaccine and delayed meningococcal vaccine (group 1)
Study: 34579786
Drug: Immediate nonavalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate nonavalent HPV vaccine and delayed meningococcal vaccine (group 2)
Study: 34579786
Drug: Immediate meningococcal
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate meningococcal vaccine and delayed HPV vaccine (group 3)
Study: 34580336
Drug: Durvalumab and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab and Paclitaxel combination therapy
Study: 34580404
Drug: TENS-L (left-sided
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS-L (left-sided shoulder TENS)
Study: 34580673
Drug: 1 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 µg NDV-HXP-S vaccine
Study: 34580673
Drug: 3 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 µg NDV-HXP-S vaccine
Study: 34580673
Drug: 10 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µg NDV-HXP-S vaccine
Study: 34580673
Drug: 3 µg+CpG1018
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 µg+CpG1018 NDV-HXP-S vaccine
Study: 34580673
Drug: 1 µg+CpG1018
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 µg+CpG1018 NDV-HXP-S vaccine
Study: 34581764
Drug: Ruxolitinib 5
Normalized name: ruxolitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib 5 mg twice daily (DL1)
Study: 34581764
Drug: Ruxolitinib 10
Normalized name: ruxolitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib 10 mg twice daily (DL2)
Study: 34581993
Drug: LLD concurrent
Normalized name: LLDT-8
DrugBank: PG-701 (DB12252)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LLD concurrent with adolescent idiopathic scoliosis (AIS)
Study: 34581993
Drug: LLD without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LLD without concurrent AIS
Study: 34583762
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (1-ml triamcinolone 40 mg/1 ml)
Study: 34583762
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection co-administered with 1-ml of 1% lidocaine
Study: 34586417
Drug: Continuous kidney
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous kidney replacement therapy (CKRT)
Study: 34586478
Drug: Crizotinib (100-215
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizotinib (100-215 mg/m, orally once or twice-daily)
Study: 34586478
Drug: Crizotinib in
Normalized name: Product containing crizotinib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizotinib in combination with dasatinib
Study: 34587913
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (EVT) for AIS in patients with AF
Study: 34587913
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (EVT) for AIS in patients without AF
Study: 34588193
Drug: Intravenous tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous tocilizumab (8 mg·kg)
Study: 34588274
Drug: Activities of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities of daily living (ADL) independence
Study: 34589984
Drug: Rociletinib 500
Normalized name: rociletinib
DrugBank: Rociletinib (DB11907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rociletinib 500 mg twice daily
Study: 34589984
Drug: Rociletinib 625
Normalized name: rociletinib
DrugBank: Rociletinib (DB11907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rociletinib 625 mg twice daily
Study: 34589984
Drug: Rociletinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rociletinib (500 mg and 625 mg twice daily) in T790M-positive patients
Study: 34590034
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg, flat dose on day 1, every 3 weeks for 2 years) plus Amrubicin (40 mg/m2)
Study: 34590052
Drug: Xentuzumab 1000
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Xentuzumab 1000 mg/wk plus afatinib 40 mg/d
Study: 34590052
Drug: Xentuzumab 1000
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Xentuzumab 1000 mg/wk plus afatinib 40 mg/d (part A)
Study: 34590052
Drug: Xentuzumab 1000
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Xentuzumab 1000 mg/wk plus afatinib 40 mg/d (part B)
Study: 34590610
Drug: Gamma Secretase
Normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma Secretase Inhibitor AL101
Study: 34592798
Drug: Aripiprazole Once
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole Once Monthly
Study: 34592798
Drug: Daily Oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Oral Atypical Antipsychotic Treatment
Study: 34593270
Drug: Fractional (1/5th
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional (1/5th dose-volume) RTS,S/AS01
Study: 34593600
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (EVT) for acute large vessel occlusion (LVO)
Study: 34594036
Drug: BNT162b2 mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 mRNA vaccine (first dose)
Study: 34594036
Drug: BNT162b2 mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 mRNA vaccine (second dose)
Study: 34594036
Drug: BNT162b2 mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 mRNA vaccine (third dose)
Study: 34596039
Drug: Variable negative
Normalized name: Ferric carbonate, ferric hydroxide, ferrous hydroxide (variable mixture)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variable negative external pressure (vNEP) therapy
Study: 34597119
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate 1 g daily plus prednisone 10 mg and luteinizing hormone-releasing hormone agonist until progression or unacceptable toxicities
Study: 34598945
Drug: MK-4830 monotherapy
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-4830 monotherapy
Study: 34598945
Drug: MK-4830 in
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-4830 in combination with pembrolizumab
Study: 34598945
Drug: MK-4830 monotherapy
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-4830 monotherapy and combination therapy
Study: 34599020
Drug: PD-L1-targeted CD47
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PD-L1-targeted CD47 bispecific antibody
Study: 34599023
Drug: Sitravatinib 120
Normalized name: Sitravatinib
DrugBank: Sitravatinib (DB15036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitravatinib 120 mg daily from day 1 up to 48 hours pre-surgery and nivolumab 240 mg on day 15.
Study: 34599042
Drug: Second wave
Normalized name: 60 Second
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second wave antibodies treatment (specific details not provided)
Study: 34599144
Drug: Roux-en-Y gastric
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roux-en-Y gastric bypass (RYGB) treatment
Study: 34600119
Drug: Composite of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite of major adverse clinical events during hospitalization (including mortality, mechanical ventilation, high-flow nasal oxygen therapy, prone positioning, sepsis, systemic inflammatory response syndrome, and embolic events)
Study: 34600820
Drug: rhHNS IT
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhHNS IT (10 mg, 45 mg, 90 mg)
Study: 34601646
Drug: Low dosage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dosage of corticosteroids (methylprednisolone 1 mg/kg)
Study: 36931078
Drug: Q6W dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q6W dosing of natalizumab
Study: 34603507
Drug: Q4W dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q4W dosing of natalizumab
Study: 34604072
Drug: Durvalumab 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab 1500 mg IV every 4 weeks for up to 1 year
Study: 34604752
Drug: Avelumab 10
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab 10 mg/kg IV Q2W added to first monthly temozolomide cycle
Study: 34604901
Drug: Linezolid 1200
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid 1200 mg daily
Study: 34604901
Drug: Linezolid 600
Normalized name: linezolid 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid 600 mg daily
Study: 34604901
Drug: Linezolid dose
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid dose reduction from 1200 mg to 600 mg based on hemoglobin monitoring
Study: 34605552
Drug: Tripegfilgrastim 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripegfilgrastim 60 μg/kg
Study: 34605552
Drug: Tripegfilgrastim 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripegfilgrastim 100 μg/kg
Study: 34606062
Drug: Switching to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching to lipophilic atorvastatin
Study: 34606437
Drug: Solriamfetol (75-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solriamfetol (75-150 mg/day for narcolepsy; 37.5-150 mg/day for OSA)
Study: 34607210
Drug: Veliparib 120
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib 120 mg BID + nivolumab + carboplatin + paclitaxel (C/PAC)
Study: 34607210
Drug: Veliparib 240
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib 240 mg BID + nivolumab + carboplatin + pemetrexed (C/PEM)
Study: 34607210
Drug: Veliparib (80-240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib (80-240 mg BID) + nivolumab + C/PEM
Study: 34607222
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy (200 mg pembrolizumab + 75 mg cisplatin, 4 cycles every 3 weeks)
Study: 34607341
Drug: pegylated IFN-α
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegylated IFN-α (pegIFNα) administered at 180 μg every 14 days for 4 doses starting at day -1 before HCT
Study: 34607348
Drug: Cladribine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cladribine 0.15 mg/kg on days 1 to 5 with 8 weekly rituximab doses of 375 mg/m2 beginning day 1
Study: 34607348
Drug: Cladribine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cladribine 0.15 mg/kg with rituximab
Study: 34607575
Drug: SPCQ (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPCQ (single treatment with SP plus chloroquine)
Study: 34607575
Drug: SPAZ (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPAZ (monthly treatment with sulphadoxine-pyrimethamine plus azithromycin)
Study: 34607609
Drug: Molecularly matched
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecularly matched therapy (≥ 1 therapy)
Study: 34607609
Drug: Personalized combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized combination therapies targeting molecular alterations
Study: 34607873
Drug: Hysterectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hysterectomy with vaginal vault suspension
Study: 34607899
Drug: TIL-based ACT
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIL-based ACT with checkpoint inhibitors (Ipilimumab 3 mg/kg prior to tumor resection and Nivolumab 3 mg/kg every 2 weeks for 4 doses)
Study: 34607899
Drug: TIL-based ACT
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIL-based ACT with checkpoint inhibitors
Study: 34608631
Drug: Efgartigimod 25
Normalized name: Efgartigimod alfa
DrugBank: Efgartigimod alfa (DB15270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Efgartigimod 25 mg/kg
Study: 34608859
Drug: Responders to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Responders to MAD treatment
Study: 34608859
Drug: Nonresponders to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonresponders to MAD treatment
Study: 34609691
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiotherapy (SBRT) with a single 25-Gy dose
Study: 34610607
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue (1.5 mg kg-1 intravenously)
Study: 34610756
Drug: Anlotinib, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib, dosage and duration not specified
Study: 34610874
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention (PCI) with second-generation drug-eluting stents (DES)
Study: 34610874
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention (PCI) with second-generation drug-eluting stents (DES) in patients with left main involvement